Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MAIA Biotechnology, Inc. ( (MAIA) ) has shared an update.
On December 10, 2025, MAIA Biotechnology announced a significant advancement in the treatment of advanced non-small cell lung cancer (NSCLC) with their telomere-targeting agent, ateganosine. This new therapeutic class aims to address the unmet medical needs of patients who do not respond to current therapies like checkpoint inhibitors or chemotherapy. The company has received Fast Track Designation from the U.S. FDA and is initiating a Phase 3 trial, positioning itself strategically in the oncology market. The potential success of ateganosine could redefine treatment paradigms for NSCLC and extend its impact across other cancer types, supported by FDA Orphan Drug Designations for glioblastoma, hepatocellular carcinoma, and small cell lung cancer.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a targeted therapy and immuno-oncology company focused on developing and commercializing first-in-class drugs with novel mechanisms of action aimed at improving and extending the lives of cancer patients. Their lead program, ateganosine (THIO), is a telomere-targeting agent in clinical development for treating non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
Average Trading Volume: 641,467
Technical Sentiment Signal: Sell
Current Market Cap: $45.55M
Learn more about MAIA stock on TipRanks’ Stock Analysis page.